SCHEMBL5376966

SCHEMBL5376966

CN(C)C(=O)n1cnc(S(=O)(=O)Cc2ccccc2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAGLA Q9Y4D2 5/20 0.43
HCRTR1 O43613 2/20 0.41
HCRTR2 O43614 2/20 0.41
TSHR P16473 2/20 0.38
HSD17B10 Q99714 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TRPV1 Q8NER1 1/20 0.38
MGLL Q99685 1/20 0.38
MAPT P10636 2/20 0.38
TP53 P04637 1/20 0.38
TLR9 Q9NR96 2/20 0.37
NPC1 O15118 1/20 0.37
MITF O75030 1/20 0.37
UBE2N P61088 1/20 0.37
PAX8 Q06710 1/20 0.37
MEN1 O00255 1/20 0.37
HSP90AA1 P07900 1/20 0.37
KMT2A Q03164 1/20 0.37
NLRP3 Q96P20 1/20 0.37
GFER P55789 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5376574 0.88 LMNA (0.40) HCRTR1HCRTR2TSHRHSD17B10SMN1; SMN2
SCHEMBL5376390 0.87 SCN4A (0.39) HCRTR1HCRTR2SMN1; SMN2MGLLMAPT
SCHEMBL5384749 0.79 DPP4 (0.40) DAGLADPP4
SCHEMBL5371714 0.76 DPP4 (0.39) DAGLASMN1; SMN2MEN1KMT2ADPP4
SCHEMBL5376197 0.76 DPP4 (0.40) DPP4
SCHEMBL5380486 0.74 DPP4 (0.42) DPP4
SCHEMBL5376216 0.72 NPC1 (0.52) DAGLATSHRHSD17B10SMN1; SMN2TRPV1
SCHEMBL5376492 0.72 DPP4 (0.42) TSHRPOLBDPP4
SCHEMBL5380508 0.71 POLB (0.55) TSHRSMN1; SMN2MAPTNPC1MEN1
SCHEMBL5384752 0.70 DPP4 (0.38) DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238720-B2 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2007-07-03 US disclosed
US-7238720-B2 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2007-07-03 US disclosed
EP-1258480-B1 Pharmaceutical use of N-Carbamoylazole derivatives EISAI CO LTD (JP) 2004-11-10 EP disclosed
EP-1258480-B1 Pharmaceutical use of N-Carbamoylazole derivatives EISAI CO LTD (JP) 2004-11-10 EP disclosed
US-20040186153-A1 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2004-09-23 US disclosed
US-20030060494-A1 Pharmaceutical use of N-carbamoylazole derivatives EISAI CO., LTD. (JP) 2003-03-27 US disclosed
EP-1258480-A1 Pharmaceutical use of N-Carbamoylazole derivatives Eisai Co., Ltd. (JP) 2002-11-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186153-A1 Pharmaceutical use of N-carbamoylazole derivatives DPP4, DPP3, DPP7 DAGLA 1213/4885HCRTR1 2857/4885HCRTR2 3612/4885
US-20030060494-A1 Pharmaceutical use of N-carbamoylazole derivatives DPP4, DPP3, DPP7 DAGLA 1213/4885HCRTR1 2857/4885HCRTR2 3612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.